TY - JOUR
T1 - The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy
AU - Augustyn, Alexander
AU - Medeiros, L. Jeffrey
AU - Ludmir, Ethan B.
AU - Gunther, Jillian
AU - Fang, Penny
AU - Li, Shaoying
AU - Ok, Chi Young
AU - Bankston, Mikaela E.
AU - Verma, Vivek
AU - Pasalic, Dario
AU - Ahmed, Sairah
AU - Nastoupil, Loretta J.
AU - Westin, Jason R.
AU - Strati, Paolo
AU - Neelapu, Sattva S.
AU - Nair, Ranjit
AU - Steiner, Raphael E.
AU - Iyer, Swaminathan P.
AU - Rodriguez, Alma
AU - Fayad, Luis E.
AU - Flowers, Christopher R.
AU - Dabaja, Bouthaina S.
AU - Pinnix, Chelsea C.
N1 - Funding Information:
This work was supported in part by the National Institutes of Health National Cancer Institute, Cancer Center Support (Core) [Grant CA 016672] to The University of Texas MD Anderson Cancer Center.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a median follow-up of 31.1 months (95% CI 27.4 − 34.8), 4 relapses occurred. The 3-year progression free survival (PFS), overall survival (OS), and loco-regional relapse free survival (LRFS) for the cohort were 95%, 96%, and 100%, respectively. There were no differences in OS, PFS, or LRFS based on COO or MYC/Bcl-2 dual expression (DE). Similarly, patients with MYC translocations without BCL2 or BCL6 rearrangements did not have worse outcomes. Consolidative RT produced excellent local control, regardless of DLBCL biology, with one late in-field failure.
AB - We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a median follow-up of 31.1 months (95% CI 27.4 − 34.8), 4 relapses occurred. The 3-year progression free survival (PFS), overall survival (OS), and loco-regional relapse free survival (LRFS) for the cohort were 95%, 96%, and 100%, respectively. There were no differences in OS, PFS, or LRFS based on COO or MYC/Bcl-2 dual expression (DE). Similarly, patients with MYC translocations without BCL2 or BCL6 rearrangements did not have worse outcomes. Consolidative RT produced excellent local control, regardless of DLBCL biology, with one late in-field failure.
KW - BCL2
KW - Lymphoma
KW - MYC
KW - consolidative radiation
KW - diffuse large B-cell lymphoma
KW - immunophenotype
UR - http://www.scopus.com/inward/record.url?scp=85099797661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099797661&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1869965
DO - 10.1080/10428194.2020.1869965
M3 - Article
C2 - 33480830
AN - SCOPUS:85099797661
SN - 1042-8194
VL - 62
SP - 1361
EP - 1369
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -